<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">680091</article-id><article-id pub-id-type="doi">10.26442/00403660.2025.08.203336</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Structural and functional parameters of erythrocytes as predictors of unfavorable outcome in patients with colorectal cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Структурно-функциональные параметры эритроцитов как предикторы неблагоприятного исхода у пациентов с колоректальным раком</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0077-3823</contrib-id><name-alternatives><name xml:lang="en"><surname>Kruchinina</surname><given-names>Margarita V.</given-names></name><name xml:lang="ru"><surname>Кручинина</surname><given-names>Маргарита Витальевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. лаб. гастроэнтерологии, вед. науч. сот. лаб. гастроэнтерологии; проф. каф. пропедевтики внутренних болезней</p></bio><email>kruchmargo@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5156-2842</contrib-id><name-alternatives><name xml:lang="en"><surname>Osipenko</surname><given-names>Marina F.</given-names></name><name xml:lang="ru"><surname>Осипенко</surname><given-names>Марина Федоровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней</p></bio><email>kruchmargo@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9254-4192</contrib-id><name-alternatives><name xml:lang="en"><surname>Gromov</surname><given-names>Andrey A.</given-names></name><name xml:lang="ru"><surname>Громов</surname><given-names>Андрей Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, ст. науч. сотр. лаб. клинических биохимических и гормональных исследований терапевтических заболеваний, руководитель Центра профилактики тромбозов</p></bio><email>kruchmargo@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-6776-3401</contrib-id><name-alternatives><name xml:lang="en"><surname>Starikov</surname><given-names>Andrey V.</given-names></name><name xml:lang="ru"><surname>Стариков</surname><given-names>Андрей Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>врач-онколог</p></bio><email>kruchmargo@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Internal and Preventive Medicine</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт терапии и профилактической медицины</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Novosibirsk State Medical University</institution></aff><aff><institution xml:lang="ru">Новосибирский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Novosibirsk Regional Oncology Dispensary</institution></aff><aff><institution xml:lang="ru">Новосибирский областной онкологический диспансер</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-08-28" publication-format="electronic"><day>28</day><month>08</month><year>2025</year></pub-date><volume>97</volume><issue>8</issue><issue-title xml:lang="en">Treatment issues</issue-title><issue-title xml:lang="ru">Вопросы лечения</issue-title><fpage>668</fpage><lpage>679</lpage><history><date date-type="received" iso-8601-date="2025-05-21"><day>21</day><month>05</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-06-02"><day>02</day><month>06</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/680091">https://ter-arkhiv.ru/0040-3660/article/view/680091</self-uri><abstract xml:lang="en"><p><bold>Aim.</bold> Identification the characteristics of fatty acids (FAs) in erythrocyte membranes and in blood serum, as well as the electrical and viscoelastic parameters of erythrocytes to assess their ability to be predictors of an unfavorable outcome in patients with colorectal cancer (CRC).</p> <p><bold>Materials and methods.</bold> 112 people with an average age of 63.1 ± 9.5 years (62 men, 50 women) with CRC of stages I–IV were examined. The patients were divided into 2 groups depending on the outcome of the disease after 6 years of follow-up: group 1 – with stabilization of the disease (<italic>n</italic> = 55), group 2 (<italic>n</italic> = 57) – with an unfavorable outcome. The FA composition of erythrocyte membranes and blood serum was studied using gas chromatography/mass spectrometry, a system based on three Agilent 7000B quadrupoles (USA). The electrical and viscoelastic parameters of erythrocytes were studied using the method of dielectrophoresis.</p> <p><bold>Results.</bold> An unfavorable outcome in patients with CRC is associated with elevated levels of docosapentaenoic acid (C22:5n-3) (<italic>p</italic> = 0.0003), docosahexaenoic acid (C22:6n-3) (<italic>p</italic> = 0.001), docosathetraenoic acid (C22:4n-6) (<italic>p</italic> = 0.004), and total omega-3 polyunsaturated fatty acids (PUFA) (<italic>p</italic> = 0.0004) in erythrocyte membranes, eicosadienoic acid (C20:2 n-6) in erythrocyte membranes (<italic>p</italic> = 0.03) and blood serum (<italic>p</italic> = 0.01), and, conversely, reduced levels of ratios saturated fatty acids (SFA)/PUFA (<italic>p</italic> = 0.004), SFA / unsaturated fatty acids (USFA) (<italic>p</italic> = 0.01) and concentrations of myristic FA (C14:0) (<italic>p</italic> = 0.03) in erythrocyte membranes, as well as with a number of changes in electrical, viscoelastic parameters of red blood cells: with increased hemolysis of red blood cells at high frequencies (10<sup>6 </sup>Hz – <italic>p</italic> = 0.0006 and 5 × 10<sup>5 </sup>Hz – <italic>p</italic> = 0.046), increased aggregation indices at low frequencies (10<sup>5 </sup>Hz – <italic>p</italic> = 0.04 and 5 × 10<sup>4 </sup>Hz – <italic>p</italic> = 0.047), as well as a shift in the crossover frequency to the high frequency range (<italic>p</italic> = 0.036). In patients with stages 1–2 of CRC, omega-6 PUFAs, eicosadienoic acid C20:2n-6 (<italic>p</italic> = 0.006), docosatetraenoic acid C22:4n-6 (<italic>p</italic> = 0.012), were of the greatest importance for differentiating disease outcomes, while total content omega-3 PUFAs in erythrocyte membranes (<italic>p</italic> = 0.0129), docosahexaenoic acid C22:6 n-3 (<italic>p</italic> = 0.0169), total content (C20:5n-3+C22:6n-3) in erythrocyte membranes (<italic>p</italic> = 0.0198), docosapentaenoic acid C22:5 n-3 (<italic>p</italic> = 0.022) were slightly less important. As in the general group of patients with CRC, the degree of hemolysis at a frequency of 10<sup>6 </sup>Hz was a predictor of an unfavorable outcome in people with early stages of the oncological process. ROC analysis revealed a high potential of palmitic acid in erythrocyte membranes to predict an unfavorable CRC outcome (AUC 0.786, 95% confidence interval 0.638–0.901, sensitivity 84.4%, specificity 68.2%). The diagnostic model, which included five parameters – erythrocyte levels C16:0, ratio SFA/PUFA, total USFA, total PUFA, and serum levels C20:2n-6, had an AUC of 0.663 (95% confidence interval 0.483–0.801) with the highest sensitivity of 85.2%, but not high specificity of 60.1% for predicting an unfavorable outcome in CRC.</p> <p><bold>Conclusion.</bold> Fatty acids of erythrocyte membranes, blood serum, electrical, and viscoelastic parameters of erythrocytes should be considered as promising biomarker predictors in patients with CRC that require further study.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Выявить особенности жирных кислот в мембранах эритроцитов и сыворотке крови, электрические и вязкоупругие параметры эритроцитов для оценки их способности быть предикторами неблагоприятного исхода у пациентов с колоректальным раком (КРР).</p> <p><bold>Материалы и методы.</bold> Обследованы 112 человек – средний возраст 63,1 ± 9,5 года (62 мужчины, 50 женщин) с КРР I–IV стадий. Пациенты разделены на 2 группы в зависимости от исхода заболевания через 6 лет наблюдения: 1-я группа – со стабилизацией заболевания (<italic>n</italic> = 55), 2-я группа (<italic>n</italic> = 57) – с неблагоприятным исходом. Исследование жирных кислот (ЖК) состава мембран эритроцитов, сыворотки крови проведено с помощью газовой хроматографии/масс-спектрометрии – системы на основе трех квадруполей Agilent 7000B (США). Электрические, вязкоупругие параметры эритроцитов изучены с использованием метода диэлектрофореза.</p> <p><bold>Результаты.</bold> Неблагоприятный исход у пациентов с КРР ассоциирован с повышенными уровнями докозапентаеновой С22:5n-3 (<italic>p</italic> = 0,0003), докозагексаеновой С22:6n-3 (<italic>p</italic> = 0,001), докозатетраеновой С22:4n-6 (<italic>p</italic> = 0,004), суммарного содержания омега-3 полиненасыщенных жирных кислот (ПНЖК) (<italic>p</italic> = 0,0004) в мембранах эритроцитов, эйкозадиеновой кислоты (C20:2n-6) в мембранах эритроцитов (<italic>p</italic> = 0,03) и сыворотке крови (<italic>p</italic> = 0,01) и, напротив, сниженными уровнями соотношений насыщенные жирные кислоты (НЖК) / ПНЖК (<italic>p</italic> = 0,004), НЖК / ненасыщенные жирные кислоты (ННЖК) (<italic>p</italic> = 0,01) и концентрации миристиновой ЖК С14:0 (<italic>p</italic> = 0,03) в мембранах эритроцитов, а также рядом изменений электрических, вязкоупругих параметров эритроцитов: с повышенным гемолизом эритроцитов на высоких частотах (10<sup>6</sup> Гц – <italic>p</italic> = 0,0006 и 5 × 10<sup>5</sup> Гц – <italic>p</italic> = 0,046), повышенными индексами агрегации на низких частотах (10<sup>5</sup> Гц – <italic>p</italic> = 0,04 и 5 × 10<sup>4</sup> Гц – <italic>p</italic> = 0,047), а также смещением равновесной частоты в высокочастотный диапазон (<italic>p</italic> = 0,036). У пациентов с I–II стадиями КРР наибольшую значимость для дифференцирования исходов заболевания имели омега-6 ПНЖК – эйкозадиеновая кислота C20:2n-6 (<italic>p</italic> = 0,006), докозатетраеновая кислота С22:4n-6 (<italic>p</italic> = 0,012), несколько меньшую – омега-3 ПНЖК – суммарное содержание их в мембранах эритроцитов (<italic>p</italic> = 0,0129), докозагексаеновая кислота С22:6 n-3 (<italic>p</italic> = 0,0169), суммарное содержание (С20:5n-3 + С22:6n-3) в мембранах эритроцитов (<italic>p</italic> = 0,0198), докозапентаеновая кислота С22:5n-3 (<italic>p</italic> = 0,022). Как и в общей группе пациентов с КРР, степень гемолиза на частоте 10<sup>6</sup> Гц была предиктором неблагоприятного исхода у лиц с ранними стадиями онкологического процесса. При проведении ROC-анализа выявлен высокий потенциал пальмитиновой кислоты в мембранах эритроцитов для предикции неблагоприятного исхода КРР (AUC 0,786, 95% доверительный интервал 0,638–0,901, чувствительность 84,4%, специфичность 68,2%). Диагностическая модель, включающая 5 параметров – эритроцитарные уровни С16:0, НЖК/ПНЖК, ННЖК, ПНЖК и сывороточный уровень С20:2n-6, – имела AUC 0,663 (95% доверительный интервал 0,483–0,801) с наиболее высокой чувствительностью (85,2%), но невысокой специфичностью (60,1%) для прогноза неблагоприятного исхода при КРР.</p> <p><bold>Заключение.</bold> ЖК мембран эритроцитов, сыворотки крови, электрические, вязкоупругие параметры эритроцитов следует рассматривать как перспективные биомаркеры-предикторы у пациентов с КРР, требующие дальнейшего изучения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>colorectal cancer</kwd><kwd>prognosis</kwd><kwd>fatty acids</kwd><kwd>serum</kwd><kwd>erythrocytes</kwd><kwd>dielectrophoresis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>колоректальный рак</kwd><kwd>прогноз</kwd><kwd>жирные кислоты</kwd><kwd>сыворотка</kwd><kwd>эритроциты</kwd><kwd>диэлектрофорез</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The work was carried out under the State assignment within the framework of the budget theme “Study of molecular genetic and molecular biological mechanisms of development of common therapeutic diseases in Siberia to improve approaches to their early diagnosis and prevention”, 2024–2028 (FWNR-2024-0004)</funding-statement><funding-statement xml:lang="ru">Работа выполнена по Государственному заданию в рамках бюджетной темы «Изучение молекулярно-генетических и молекулярно-биологических механизмов развития распространенных терапевтических заболеваний в Сибири для совершенствования подходов к их ранней диагностике и профилактике», 2024–2028 гг. (FWNR-2024-0004)</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. DOI:10.3322/caac.21834</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Van der Geest LG, Lam-Boer J, Koopman M, et al. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32(5):457-65. DOI:10.1007/s10585-015-9719-0</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>White A, Joseph D, Rim SH, et al. Colon cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer. 2017;123(Suppl. 24):5014-36. DOI:10.1002/cncr.31076</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Zhang Y, Wang Y, Zhang B, et al. Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer. Biomed Pharmacother. 2023;163:114786. DOI:10.1016/j.biopha.2023.114786</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Gu J, Xiao Y, Shu D, et al. Metabolomics Analysis in Serum from Patients with Colorectal Polyp and Colorectal Cancer by 1H-NMR Spectrometry. Dis Markers. 2019;2019:3491852. DOI:10.1155/2019/3491852</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Martín-Blázquez A, Díaz C, González-Flores E, et al. Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer. Sci Rep. 2019;9(1):20198. DOI:10.1038/s41598-019-55952-8</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Santos CR, Schulze A. Lipid Metabolism in Cancer: Lipid Metabolism in Cancer. FEBS J. 2012;279(15):2610-23. DOI:10.1111/j.1742-4658.2012.08644.x</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Del Solar V, Lizardo DY, Li N, et al. Differential Regulation of Specific Sphingolipids in Colon Cancer Cells during Staurosporine-Induced Apoptosis. Chem Biol. 2015;22:1662-70. DOI:10.1016/j.chembiol.2015.11.004</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Sun H, Zhang L, Wang Z, et al. Single-cell transcriptome analysis indicates fatty acid metabolism-mediated metastasis and immunosuppression in male breast cancer. Nat Commun. 2023;14(1):5590. DOI:10.1038/s41467-023-41318-2</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>El Hindi K, Brachtendorf S, Hartel JC, et al. Hypoxia induced deregulation of sphingolipids in colon cancer is a prognostic marker for patient outcome. Biochim Biophys Acta Mol Basis Dis. 2024;1870(1):166906. DOI:10.1016/j.bbadis.2023.166906</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Krishnan ST, Winkler D, Creek D, et al. Staging of colorectal cancer using lipid biomarkers and machine learning. Metabolomics. 2023;19(10):84. DOI:10.1007/s11306-023-02049-z</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Кручинина М.В., Светлова И.О., Громов А.А., и др. Колоректальный рак и изменения липидома. Новосибирск: ООО «Офсет-ТМ», 2020 [Kruchinina MV, Svetlova IO, Gromov AA, et al. Kolorektal'nyi rak i izmeneniia lipidoma. Novosibirsk: Offset-TM LLC, 2020 (in Russian)].</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Spell DW, Jones DV Jr, Harper WF, David Bessman J. The value of a complete blood count in predicting cancer of the colon. Cancer Detect Prev. 2004;28(1):37-42. DOI:10.1016/j.cdp.2003.10.002</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ellingsen TS, Lappegard J, Skjelbakken T, et al. Impact of red cell distribution width on future risk of cancer and all-cause mortality among cancer patients – the Tromsø Study. Haematologica. 2015;100(10): e387-9. DOI:10.3324/haematol.2015.129601</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Santos-Silva MA, Sousa N, Majar M, et al. Pattern recognition of hematological profiles of tumors of the digestive tract: an exploratory study. Front Med (Lausanne). 2023;10:1208022. DOI:10.3389/fmed.2023.1208022</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Rees PA, Clouston HW, Duff S, Kirwan CC. Colorectal cancer and thrombosis. Int J Colorectal Dis. 2018;33(1):105-8. DOI:10.1007/s00384-017-2909-2</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Shen J, Qin X, Zeng X, et al. Hemoglobin levels in red blood cells and risk of colorectal cancer: A causal investigation based on Mendelian randomization. Medicine (Baltimore). 2024;103(48):e40562. DOI:10.1097/MD.0000000000040562</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Kruchinina MV, Prudnikova YaI, Gromov AA, et al. New opportunities for colorectal cancer diagnostics using an optical cell detection system based on dielectrophoresis. Optics and Spectroscopy. 2019;126(5): 568-73. DOI:10.1134/S0030400X19050163</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kruchinina MV, Gromov A A, Shcherbakova LV, et al. Electric and viscoelastic parameters of erythrocytes in models for diagnostics of adenomatous polyps and stages of colorectal cancer in optical detection of cells in an inhomogeneous alternating electric field. Optics and Spectroscopy. 2021;129(6):772-85. DOI:10.1134/S0030400X21060060</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Скоулфилд Д.Г., Энг К. Колоректальный рак. Диагностика и тактика лечения. Пер. с анг. под ред. Ю.А. Шелыгина. М.: Практическая медицина, 2019 [Scoulfield DG, Eng K. Colorectal cancer. Diagnostika i taktika lecheniia. Trans. from English. Moscow: Practical Medicine, 2019 (in Russian)].</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Генералов К.В., Кручинина М.В., Сафатов А.С., и др. Диэлектрофорез в медицине. Новосибирск: ООО «Офсет-ТМ», 2024 [Generalov KV, Kruchinina MV, Safatov AS, et al. Dielektroforez v meditsine. Novosibirsk: Offset-TM LLC, 2020 (in Russian)].</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Кручинина М.В., Кручинин В.Н., Прудникова Я.И., и др. Исследование уровня жирных кислот мембран эритроцитов и сыворотки крови у пациентов с колоректальным раком г. Новосибирска. Успехи молекулярной онкологии. 2018;5(2):50-61 [Kruchinina MV, Kruchinin VN, Prudnikova YaI, et al. Study of the level of fatty acids in erythrocyte membranes and serum of patients with colorectal cancer in Novosibirsk. Advances in Molecular Oncology. 2018;5(2):50-61 (in Russian)]. DOI:10.17650/2313-805X-2018-5-2-50-61</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Breiman L. Random Forests. Machine Learning. 2001;45:5-32. DOI:10.1023/A:1010933404324</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Ecker J, Benedetti E, Kindt ASD, et al. The Colorectal Cancer Lipidome: Identification of a Robust Tumor-Specific Lipid Species Signature. Gastroenterology. 2021;161(3):910-23.e19. DOI:10.1053/j.gastro.2021.05.009</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Machala M, Procházková J, Hofmanová J, et al. Colon cancer and perturbations of the sphingolipid metabolism. Int J Mol Sci. 2019;20:6051. DOI:10.3390/ijms20236051</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Bandu R, Mok HJ, Kim KP. Phospholipids as cancer biomarkers: Mass spectrometry-based analysis. Mass Spectrom. Rev. 2018;37:107-38. DOI:10.1002/mas.21510</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Mirnezami R, Spagou K, Vorkas PA, et al. Chemical mapping of the colorectal cancer microenvironment via MALDI imaging mass spectrometry (MALDI-MSI) reveals novel cancer-associated field effects. Mol Oncol. 2014;8:39-49. DOI:10.1016/j.molonc.2013.08.010</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Hoy AJ, Nagarajan SR, Butler LM. Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat Rev Cancer. 2021;21(12):753-66. DOI:10.1038/s41568-021-00388-4</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Zhao G, Tan Y, Cardenas H, et al. Ovarian cancer cell fate regulation by the dynamics between saturated and unsaturated fatty acids. Proc Natl Acad Sci USA. 2022;119(41):e2203480119. DOI:10.1073/pnas.2203480119</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Igal RA. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis. 2010;31(9):1509-15. DOI:10.1093/carcin/bgq131</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Gradilla AC, Sanchez-Hernandez D, Brunt L, Scholpp S. From top to bottom: Cell polarity in Hedgehog and Wnt trafficking. BMC Biol. 2018;16(1):37. DOI:10.1186/s12915-018-0511-x</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693-8. DOI:10.1038/s41586-019-1707-0</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Aglago EK, Murphy N, Huybrechts I, et al. Dietary intake and plasma phospholipid concentrations of saturated, monounsaturated and trans fatty acids and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. Int J Cancer. 2021. DOI:10.1002/ijc.33615</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Du W, Hua F, Li X, et al. Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation. Cancer Discov. 2021;11(7):1826-43. DOI:10.1158/2159-8290.CD-20-1571</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Zhang M, Zhou L, Xu Y, et al. A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis. Nature. 2020;586(7829):434-9. DOI:10.1038/s41586-020-2799-2</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Zhang Q, Yang X, Wu J, et al. Reprogramming of palmitic acid induced by dephosphorylation of ACOX1 promotes β-catenin palmitoylation to drive colorectal cancer progression. Cell Discov. 2023;9(1):26. DOI:10.1038/s41421-022-00515-x</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>De Araujo Junior RF, Eich C, Jorquera C, et al. Ceramide and palmitic acid inhibit macrophage-mediated epithelial-mesenchymal transition in colorectal cancer. Mol Cell Biochem. 2020;468(1-2):153-68. DOI:10.1007/s11010-020-03719-5</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Yu G, Luo H, Zhang N, et al. Loss of p53 Sensitizes Cells to Palmitic Acid-Induced Apoptosis by Reactive Oxygen Species Accumulation. Int J Mol Sci. 2019;20(24):6268. DOI:10.3390/ijms20246268</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Deng S, Wang J, Zou F, et al. Palmitic Acid Accumulation Activates Fibroblasts and Promotes Matrix Stiffness in Colorectal Cancer. Cancer Res. 2025;85(10):1784-802. DOI:10.1158/0008-5472.CAN-24-2892</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut. 2012;61(1):135-49. DOI:10.1136/gut.2010.233718</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015;1851(4):469-84. DOI:10.1016/j.bbalip.2014.08.010</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>D'Angelo S, Motti ML, Meccariello R. ω-3 and ω-6 Polyunsaturated Fatty Acids, Obesity and Cancer. Nutrients. 2020;12(9):2751. DOI:10.3390/nu12092751</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105-15. DOI:10.1042/BST20160474</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Volpato M, Hull MA. Omega-3 polyunsaturated fatty acids as adjuvant therapy of colorectal cancer. Cancer Metastasis Rev. 2018;37(2-3): 545-55. DOI:10.1007/s10555-018-9744-y</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Mayer K, Seeger W. Fish oil in critical illness. Curr Opin Clin Nutr Metab Care. 2008;11(2):121-7. DOI:10.1097/MCO.0b013e3282f4cdc6</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Singer P, Shapiro H, Theilla M, et al. Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med. 2008;34(9):1580-92. DOI:10.1007/s00134-008-1142-4</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Guo Y, Ma B, Li X, et al. n-3 PUFA can reduce IL-6 and TNF levels in patients with cancer. Br J Nutr. 2023;129(1):54-65. DOI:10.1017/S0007114522000575</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Kavyani Z, Musazadeh V, Fathi S, et al. Efficacy of the omega-3 fatty acids supplementation on inflammatory biomarkers: An umbrella meta-analysis. Int Immunopharmacol. 2022;111:109104. DOI:10.1016/j.intimp.2022.109104</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Chiang N, Serhan CN. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med. 2017;58:114-29. DOI:10.1016/j.mam.2017.03.005</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Lam CN, Watt AE, Isenring EA, et al. The effect of oral omega-3 polyunsaturated fatty acid supplementation on muscle maintenance and quality of life in patients with cancer: A systematic review and meta-analysis. Clin Nutr. 2021;40(6):3815-26. DOI:10.1016/j.clnu.2021.04.031</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Lee SY, Lee J, Park HM, et al. Impact of Preoperative Immunonutrition on the Outcomes of Colon Cancer Surgery: Results from a Randomized Controlled Trial. Ann Surg. 2023;277(3):381-6. DOI:10.1097/SLA.0000000000005140</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Pradelli L, Mayer K, Klek S, et al. Omega-3 fatty acids in parenteral nutrition – A systematic review with network meta-analysis on clinical outcomes. Clin Nutr. 2023;42(4):590-9. DOI:10.1016/j.clnu.2023.02.008</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Bakker N, van den Helder RS, Stoutjesdijk E, et al. Effects of perioperative intravenous ω-3 fatty acids in colon cancer patients: a randomized, double-blind, placebo-controlled clinical trial. Am J Clin Nutr. 2020;111(2):385-95. DOI:10.1093/ajcn/nqz281</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Hofmanová J, Slavík J, Ciganek M, et al. Complex Alterations of Fatty Acid Metabolism and Phospholipidome Uncovered in Isolated Colon Cancer Epithelial Cells. Int J Mol Sci. 2021;22(13):6650. DOI:10.3390/ijms22136650</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Cottet V, Vaysse C, Scherrer ML, et al. Fatty acid composition of adipose tissue and colorectal cancer: a case-control study. Am J Clin Nutr. 2015;101(1):192-201. DOI:10.3945/ajcn.114.088948</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Liu H, Chen J, Shao W, et al. Efficacy and safety of Omega-3 polyunsaturated fatty acids in adjuvant treatments for colorectal cancer: A meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1004465. DOI:10.3389/fphar.2023.1004465</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Yessoufou A, Plé A, Moutairou K, et al. Docosahexaenoic acid reduces suppressive and migratory functions of CD4+CD25+ regulatory T-cells. J Lipid Res. 2009;50(12):2377-88. DOI:10.1194/jlr.M900101-JLR200</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Woodworth HL, McCaskey SJ, Duriancik DM, et al. Dietary fish oil alters T lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis. Cancer Res. 2010;70(20):7960-9. DOI:10.1158/0008-5472.CAN-10-1396</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181-93. DOI:10.1038/nrc2809</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Il Lee S, Zuo X, Shureiqi I. 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? Cancer Metastasis Rev. 2011; 30(3-4):481-91. DOI:10.1007/s10555-011-9321-0</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Kim GY, Lee JW, Cho SH, et al. Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29(6):915-20. DOI:10.1161/ATVBAHA.109.185793</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Ihara A, Wada K, Yoneda M, et al. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci. 2007;103(1):24-32. DOI:10.1254/jphs.fp0060651</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Radic Biol Med. 2012;52(9):2013-37. DOI:10.1016/j.freeradbiomed.2012.02.035</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Xia D, Wang D, Kim SH, et al. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med. 2012;18(2):224-6. DOI:10.1038/nm.2608</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Cen B, Lang JD, Du Y, et al. Prostaglandin E2 Induces miR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression. Gastroenterology. 2020;158(4):971-84.e10. DOI:10.1053/j.gastro.2019.11.013</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Tanaka T, Uozumi S, Morito K, et al. Metabolic conversion of C20 polymethylene-interrupted polyunsaturated fatty acids to essential fatty acids. Lipids. 2014;49(5):423-9. DOI:10.1007/s11745-014-3896-5</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Huang YS, Huang WC, Li CW, Chuang LT. Eicosadienoic acid differentially modulates production of pro-inflammatory modulators in murine macrophages. Mol Cell Biochem. 2011;358(1-2):85-94. DOI:10.1007/s11010-011-0924-0</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Wang L, Hang D, He X, et al. A prospective study of erythrocyte polyunsaturated fatty acids and risk of colorectal serrated polyps and conventional adenomas. Int J Cancer. 2021;148(1):57-66. DOI:10.1002/ijc.33190</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Soundararajan R, Maurin MM, Rodriguez-Silva J, et al. Integration of lipidomics with targeted, single cell, and spatial transcriptomics defines an unresolved pro-inflammatory state in colon cancer. Gut. 2025;74(4):586-602. DOI:10.1136/gutjnl-2024-332535</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2:612-9. DOI:10.1038/89759</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Zhao W, Prijic S, Urban BC, et al. Candidate Antimetastasis Drugs Suppress the Metastatic Capacity of Breast Cancer Cells by Reducing Membrane Fluidity. Cancer Res. 2016;76(7):2037-49. DOI:10.1158/0008-5472.CAN-15-1970</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Yang Z, Qin W, Chen Y, et al. Cholesterol inhibits hepatocellular carcinoma invasion and metastasis by promoting CD44 localization in lipid rafts. Cancer Lett. 2018;429:66-77. DOI:10.1016/j.canlet.2018.04.038</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Moleón Baca JA, Ontiveros Ortega A, Aránega Jiménez A, Granados Principal S. Cells electric charge analyses define specific properties for cancer cells activity. Bioelectrochemistry. 2022;144:108028. DOI:10.1016/j.bioelechem.2021.108028</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Moreddu R. Nanotechnology and Cancer Bioelectricity: Bridging the Gap Between Biology and Translational Medicine. Adv Sci (Weinh). 2024;11(1):e2304110. DOI:10.1002/advs.202304110</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Chaudhary P, Maharjan N, Subedi B. Microangiopathic Hemolytic Anemia as the Initial Presentation of Metastatic Signet-Ring Cell Carcinoma of the Colon: A Case Report. Cureus. 2024;16(12):e76034. DOI:10.7759/cureus.76034</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Horne MK 3rd, Cooper B. Microangiopathic hemolytic anemia with metastatic adenocarcinoma: response to chemotherapy. South Med J. 1982;75(4):503-4. DOI:10.1097/00007611-198204000-00040</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Ghirmai S, Krona A, Wu H, et al. Relationship between hemolysis and lipid oxidation in red blood cell-spiked fish muscle; dependance on pH and blood plasma. Sci Rep. 2024;14(1):1943. DOI:10.1038/s41598-024-52090-8</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Lee RA, Kim HA, Kang BY, Kim KH. Hemoglobin induces colon cancer cell proliferation by release of reactive oxygen species. World J Gastroenterol. 2006;12(35):5644-50. DOI:10.3748/wjg.v12.i35.5644</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Koukourakis MI, Giatromanolaki A, Polychronidis A, et al. Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Sci. 2006;97(7):582-8. DOI:10.1111/j.1349-7006.2006.00220.x</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Bastide NM, Pierre FH, Corpet DE. Heme iron from meat and risk of colorectal cancer: a meta-analysis and a review of the mechanisms involved. Cancer Prev Res (Phila). 2011;4(2):177-84. DOI:10.1158/1940-6207.CAPR-10-0113</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Xue X, Shah YM. Intestinal iron homeostasis and colon tumorigenesis. Nutrients. 2013;5(7):2333-51. DOI:10.3390/nu5072333</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Kucharzewski M, Braziewicz J, Majewska U, Gózdz S. Iron concentrations in intestinal cancer tissue and in colon and rectum polyps. Biol Trace Elem Res. 2003;95(1):19-28. DOI:10.1385/BTER:95:1:19</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>McSorley ST, Tham A, Steele CW, et al. Quantitative data on red cell measures of iron status and their relation to the magnitude of the systemic inflammatory response and survival in patients with colorectal cancer. Eur J Surg Oncol. 2019;45(7):1205-11. DOI:10.1016/j.ejso.2019.02.027</mixed-citation></ref></ref-list></back></article>
